DFMO tested as follow-up treatment for medulloblastoma
Original title: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called DFMO in people with a brain tumor called medulloblastoma.
Who this trial is for. This trial is for people with medulloblastoma whose tumor tests show high risk or very high risk, and for people whose tumor came back or did not respond to treatment. It is testing a drug called DFMO as maintenance therapy, which is treatment given after earlier treatment.
Where it stands. This trial has not reported results. The source does not say what the answer is. It is a study running at more than one center, and everyone involved knows who is getting DFMO. We do not know yet what it will show.
What this means, and what it doesn't
What it could mean: This is one option a person with this kind of tumor might hear about. If it sounds like your situation, you can ask your care team about it. They know your case and can tell you if it makes sense to look into.
What it doesn't mean: A trial is a test, not a proven treatment. Joining one is not a guarantee that it will help you. This is not a promise of a cure. Whether anyone can take part is decided by the trial team.
Source: ClinicalTrials.gov, August 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.